Agilus Diagnostics has strengthened its precision oncology capabilities with the launch of the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai.

The introduction of the fully automated platform marks a major advancement in molecular diagnostics, allowing the detection of clinically relevant cancer mutations within 2.5 to 3 hours. 

Conventional molecular testing methods often require several days to generate results, potentially delaying treatment decisions in time-sensitive oncology cases.

The Idylla system integrates sample processing, nucleic acid extraction, amplification and detection into a single cartridge-based workflow. By eliminating multiple manual steps and reducing pre-analytical variability, the platform delivers highly accurate and reproducible results while streamlining laboratory operations.

Among the key biomarkers detected by the system are EGFR mutations, which are commonly associated with lung cancer and are particularly prevalent in Indian and Asian populations.

The platform also identifies KRAS and NRAS mutations linked to colorectal and pancreatic cancers, as well as BRAF mutations that occur across several tumour types, including melanoma and colorectal cancer.

Dr. Anand K, MD and CEO of Agilus Diagnostics, said, “The introduction of the Idylla system at our Goregaon facility significantly enhances our molecular diagnostics capabilities and strengthens our commitment to precision medicine.”

“By enabling rapid access to critical genomic insights, we aim to empower clinicians with timely, actionable information that can improve treatment outcomes and expand access to quality cancer care,” he added.

Dr. Kunal Sharma, Vice President and Head – Integrated Onco-Pathology at Agilus Diagnostics, said, “Delivering actionable molecular insights within hours can significantly impact cancer care. The Idylla platform enables rapid detection of key mutations such as EGFR, KRAS, NRAS and BRAF with minimal manual intervention and high analytical performance.”

“This is especially valuable in scenarios where time is critical and tissue samples are limited. With this launch, we continue to strengthen our commitment to providing cutting-edge, high-quality precision diagnostics,” he said.